Clearline Capital LP Acquires New Shares in OPKO Health, Inc. (NASDAQ:OPK)

Clearline Capital LP bought a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 726,582 shares of the biotechnology company’s stock, valued at approximately $1,083,000.

A number of other institutional investors have also added to or reduced their stakes in the business. CIBC Asset Management Inc raised its stake in OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after buying an additional 8,978 shares in the last quarter. Hollencrest Capital Management lifted its stake in shares of OPKO Health by 14.0% during the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 11,020 shares during the last quarter. FMR LLC boosted its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in OPKO Health by 4.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock valued at $536,000 after purchasing an additional 17,671 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in OPKO Health in the first quarter worth about $26,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Stock Down 2.5 %

Shares of OPK opened at $1.54 on Monday. The stock has a market capitalization of $1.05 billion, a PE ratio of -8.11 and a beta of 1.65. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.75. The company’s 50-day simple moving average is $1.52 and its 200-day simple moving average is $1.46.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 199,072 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was acquired at an average cost of $1.53 per share, with a total value of $304,580.16. Following the purchase, the chief executive officer now owns 211,911,477 shares in the company, valued at approximately $324,224,559.81. This represents a 0.09 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders acquired a total of 679,255 shares of company stock worth $1,045,855 over the last 90 days. 47.26% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

OPK has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler restated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.